|
(Health-NewsWire.Net, March 30, 2020 ) Market Overview
• The Global Anti-viral therapeutics Market is expected to grow at a CAGR of 3.8% during the forecasting period (2019-2026).
• Antiviral drugs are a class of medication, which are used in treating viral infections, and most antivirals are used for specific viral infections. Antiviral drugs are sold prescription-based only and are different from antibiotics, which fight against bacterial infections. Unlike most antibiotics, antiviral medication does not destroy the target pathogen, but instead, they obstruct the development. Most antiviral drugs currently available are to help deal with herpes viruses, HIV, influenza A, and B viruses, and hepatitis B, and C viruses. Moreover, researchers are working on expanding the range of antivirals to other families of pathogens.
Download free sample: https://www.datamintelligence.com/download-sample/anti-viral-therapeutics-market
Market Dynamics
• The global market for the Antiviral Therapeutics The market is primarily driven by the growing incidents of viral infections among populations. According to UNAIDS, in 2017, there were an estimated 36.9 million people [31.1 million–43.9 million] worldwide living with HIV/AIDS, of which 1.8 million were children (15 years old and below), and an estimated 1.8 million individuals became newly infected with HIV. According to the World Health Organization (WHO), an estimated 257 million people are living with hepatitis B virus infection, and in 2015, hepatitis B resulted in 887 000 deaths. WHO estimated that 71 million people are infected with hepatitis C worldwide. Moreover, strong R&D, increasing product launches, a strong pipeline for antiviral drugs coupled with the increasing awareness on viral infections and their treatments are of the key drivers in the antiviral therapeutics market growth. For instance, in May 2019, Atriva Therapeutics GmbH announced the first dose up of its lead drug candidate ATR-002 in a Phase I clinical trial, marks the start of the clinical development of a novel host-targeted approach to treating influenza virus infections. However, the patent expiration of blockbuster drugs and the high cost of Antiviral therapeutics may hinder market progress.
Market Segmentation
• By Application, the Global Antiviral Therapeutics Market is segmented into HIV, Hepatitis, Herpes Simplex Virus, Influenza, and others. The HIV application holds the largest market share owing to its growing prevalence worldwide and an increasing number of drug launches coupled with several drugs currently in the pipeline. According to UNAIDS, in 2017, there were approximately 1.8 million people [1.4 million–2.4 million] who became newly infected with HIV worldwide and nearly 21.7 million people of the total 36.9 million people living with HIV/AIDS were receiving antiretroviral therapy. For instance, in 2018 alone, there were four drugs (Trogarzo, Biktarvy, Delstrigo, and Symtuza) approved by the FDA for the treatment of HIV. However, Hepatitis application is anticipated to show significant market growth, increasing R&D expenditure by key players, and approval of combination antiviral therapies. For instance, in May 2019, Cocrystal Pharma Inc., a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, begun patient enrolment in its Phase 2a open-label study. The study will evaluate the safety, tolerability, and preliminary efficacy of Cocrystal’s CC-31244 in combination with Daclatasvir and Sofosbuvir with and without protease inhibitors, for the treatment of hepatitis C.
• By Mechanism of Action, the Global Antiviral Therapeutics Market is segmented into Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and others. The Reverse Transcriptase Inhibitor segment held the most significant market share owing to its high demand and broad product range for the treatment of HIV.
Geographical Analysis
• North America accounts for the largest share in the global Antiviral Therapeutics market and is mainly attributed to the growing prevalence of HIV, Hepatitis infections, and Influenza in the region. According to the CDC in 2016, an estimated 38,700 people became newly infected with HIV in the US, and approximately 1.1 million people in the US are living with HIV. CDC reported a total of 3,218 cases of acute hepatitis B, with an overall incidence rate of 1.0 cases per 100,000 population in 2016 and CDC estimates that 800,000 to 2.2 million people in the United States have chronic hepatitis B. Moreover, the advanced regional healthcare infrastructure, high level of drug development, presence of established market players, rise in healthcare expenditure, and high investment in R&D activities by them are likely to boost the North America Antiviral Therapeutics market growth.
Competitive Analysis
• Several key companies have adopted merger and acquisitions policies, geographic expansion, and collaborations to help them to stand out as strong competitors in the market and also expand its sales in the global Anti-viral Therapeutics market. Moreover, the increasing FDA approvals, product launches, and robust pipeline are improving key players’ market presence.
• Major Players in the global Anti-viral Therapeutics market include Roche, Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson and Merck.
• In June 2019, Cidara Therapeutics Inc., a biotechnology company developing novel anti-infectives including immunotherapies, announced that new data from studies of CB-012, its Cloudbreak antiviral Fc-conjugate (AVC) candidate for influenza. CB-012 is the first AVC candidate generated by Cidara’s Cloudbreak anti-infective immunotherapy platform.
• In April 2019, the US FDA approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of HIV-1 infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato. This is the first FDA-approved two-drug, FDC regimen for HIV-infected adults who have never received treatment for HIV.
View full report: https://www.datamintelligence.com/research-report/anti-viral-therapeutics-market
Enquiry before buying: https://www.datamintelligence.com/enquiry/anti-viral-therapeutics-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
